Supplementary Figure 1 from Identification of High-Incidence Populations in the United States for Anti–Epstein-Barr Virus Serologic Screening for Nasopharyngeal Carcinoma
Year: 2024
Type: supplementary-materials
Abstract: Supplementary Figure 1: Natural history Markov model of endemic nasopharyngeal carcinoma (NPC). Healthy adults could develop Epstein-Barr Virus-associated (EBV) stage I NPC and progress without detection to more advanced stages of undetected disease. This is the cohort of patients with prevalent undiagnosed NPC that can be screen-detected. Each undetected stage of NPC could present symptomatically or be detected by screening. A subset of healthy adults and those with each stage of preclinical NPC are biomarker positive or negative (for each of ten biomarker combinations). At the time of screening, participants who are biomarker positive (whether healthy or those with preclinical NPC) test positive and are found to be true positives or false positives. Similarly, participants who are biomarker negative are true negatives or false negatives. Each detected (incident) case of NPC is managed with radiotherapy and/or chemotherapy, and can either be cured or develop locoregional recurrence (LRR) or distant metastasis (DM) after treatment and die from their disease. Patients with stage IVC NPC receive chemotherapy until dying from their disease. In each state, there is also the risk of remaining within the same state or dying from other causes.
Language: English
Topic: Head and Neck Cancer Studies
Subfield: Otorhinolaryngology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
OpenAlex ID: W4404933449